Tyra Biosciences Inc (TYRA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Tyra Biosciences Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 31.90 $ — 74% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 12.5% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 250 m net cash passed
- Operating cash flow covers the profits of the last three years 61 m failed
- Return on capital at 15% or higher, or up versus two years ago -50.2% failed
- Insiders hold at least 10% or are net buyers 2.9% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 62.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.57 | -2.82 – -2.31 | 0 | -27.7% | 14 |
| 12/31/2027 | -2.86 | -3.52 – -2.26 | 3 | -11.3% | 14 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.67 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.43 | – | 1 | -1.20 | -5,155.40 | -20 | -20 |
| 2025: Q1 | -0.47 | – | 0 | – | – | -26 | -26 |
| 2025: Q2 | -0.47 | – | 0 | – | – | -24 | -24 |
| 2025: Q3 | -0.50 | – | 0 | – | – | -22 | -22 |
| 2025: Q4 | -0.57 | – | 0 | -100.00 | – | -24 | -24 |
| 2026: Q1 | -0.64 | – | 0 | – | – | -33 | -33 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 0 | -3 | -4 | -0.10 | -3 | -5 | 1 |
| 2020 | 0 | -9 | -9 | -0.22 | -8 | -14 | 16 |
| 2021 | 0 | -26 | -26 | -0.63 | -24 | 302 | 307 |
| 2022 | 0 | -59 | -52 | -1.23 | -50 | 258 | 266 |
| 2023 | 0 | -80 | -69 | -1.62 | -50 | 204 | 226 |
| 2024 | 0 | -104 | -86 | -1.51 | -70 | 343 | 364 |
| 2025 | 0 | -133 | -120 | -2.01 | -95 | 259 | 283 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Tyra Biosciences, Inc., ein Biotechnologieunternehmen in der klinischen Phase, entwickelt Präzisionsmedikamente für die Biologie des Fibroblasten-Wachstumsfaktor-Rezeptors (FGFR) in den USA.
| Employees | 87 |
|---|---|
| Headquarters | Carlsbad, CA |
| Address | 2656 State Street, 92008 Carlsbad, United States |
| Phone | 619 728 4760 |
| Website | tyra.bio |
| IPO Date | 15. Sep 2021 |
| ISIN | US90240B1061 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Todd Harris Ph.D. | Co-Founder, CEO, President & Director | 1979 |
| Bhavesh Ashar M.B.A. | Chief Operating Officer | 1969 |
| Douglas Warner M.D. | Chief Medical Officer | 1972 |
| Daniel Bensen | Co-Founder & Chief Discovery Officer | 1975 |
| Julia Rueb | VP of Finance & Principal Accounting Officer | 1986 |
| Robert L. Hudkins Ph.D. | Chief Technology Officer | 1955 |
| Ronald V. Swanson Ph.D. | Chief Scientific Officer | 1963 |
| Ali D. Fawaz J.D. | General Counsel & Secretary | – |
| Sarah Honig | Senior VP of Corporate Development & Strategy | – |
| Liz Pagano | Chief Human Resources Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.